Phenprocoumon

Drug Levels and Effects:




Summary of Use during Lactation:


Phenprocoumon is not approved for sale by the US Food and Drug Administration (FDA). Limited information indicates thatanticoagulantmaternal doses of phenprocoumon produce low levels in milk. Until more data are available, shorter-actinganticoagulantsare preferred, especially if the infant is younger than 2 months.


Drug Levels:


Maternal Levels.

One mother required anticoagulation postpartum was given phenprocoumon as ananticoagulant. Milk samples were obtained on days 27, 28 and 31 postpartum when her prothrombin time and phenprocoumon serum concentrations were stable. Milk phenprocoumon concentrations varied between 26 and 76 mcg/L and concentrations were higher in hindmilk than foremilk. A complete 24-hour milk collection contained a concentration of 33 mcg/L of phenprocoumon.[1]

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Relevant published information was not found as of the revision date.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


Alternate Drugs to Consider:


Acenocoumarol,Warfarin


References:


1. von Kries R, Nocker D, Schmitz-Kummer E, de Vries JX. [Transfer of phenprocoumon in breast milk. Is oral anticoagulation with phenprocoumon a contraindication for breastfeeding?]. Monatsschr Kinderheilkd. 1993;141:505-7. PMID:8336747



Substance Identification:




Substance Name:

Phenprocoumon

CAS Registry Number:

435-97-2

Drug Class:


Anticoagulant

Administrative Information:




LactMed Record Number:


638


Last Revision Date:


Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.